Abstract: The role played by the biologically active CART 55-102 peptide in NAcc AMPH induced locomotion was investigated. When microinjected alone into this site, none of the doses of CART 55-102 tested (0.1, 0.4, 1.0 or 2.5 microg/0.5 microl/side) produced effects on locomotion during a two-h test. However, when co-injected with AMPH (2.5 microg/0.5 microl/side) into the NAcc, moderately high (2.5 microg/side) and middle to high (0.4-2.5 microg/side) doses of CART 55-102 significantly attenuated the effects of AMPH on locomotion and rearing, respective...
(read more)
Topics: 
Pharmacology
Endocrinology
Internal medicine